CytomX to Present at Upcoming Investor Conferences
Sean McCarthy , D. Phil., president and chief executive officer, will present at theCowen and Company 38th Annual Healthcare Conference onMarch 13, 2018 , at10:00 a.m. ET .Debanjan Ray , Chief Financial Officer and Head of Corporate Development, will present at the Barclay’sGlobal Health Conference onMarch 15, 2018 , at8:30 a.m. ET .
A live audio webcast for each event will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as CX-072, a PD-L1-targeting Probody therapeutic and BMS-986249, a CTLA-4-targeting Probody therapeutic, and first-in-class Probody drug conjugates against highly attractive targets, such as CX-2009, a CD166-targeting Probody drug conjugate and CX-2029, a CD71-targeting Probody drug conjugate, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, Pfizer and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
Media:
Spectrum
Christine Quern
cquern@spectrumscience.com
202-587-2588
Investors:
prahmer@troutgroup.com
646-378-2973